Vir Biotechnology, Inc. · NASDAQ:VIR
Robert Nelsen reported a 7.30% stake in Vir Biotechnology, Inc. (Schedule 13D/A)
Event Nov 4, 2026 · Filed Nov 6, 2026
Robert Nelsen reported a 7.30% stake in Vir Biotechnology, Inc., 12,508,029 shares, with active intent on Nov 4, 2026. Filed Nov 6, 2026 (Schedule 13D/A).
- Stake
- 7.30%
- Shares
- 12,508,029
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 8 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| ARCH Venture Fund IX, L.P. | 6.90% | 11,897,988 |
| ARCH Venture Fund IX Overage, L.P. | 6.90% | 11,897,988 |
| ARCH Venture Partners IX, L.P. | 6.90% | 11,897,988 |
| ARCH Venture Partners IX Overage, L.P. | 6.90% | 11,897,988 |
| ARCH Venture Partners IX, LLC | 6.90% | 11,897,988 |
| Robert Nelsen | 7.30% | 12,508,029 |
| Keith Crandell | 7.10% | 12,170,952 |
| Clinton Bybee | 7.00% | 11,989,718 |
Source
Download original · View original at SEC
Related
- Vir Biotechnology, Inc.
- Robert Nelsen
- Vir Biotechnology, Inc. shareholders
- Schedule 13D/A · Robert Nelsen · Mar 3, 2026
- Form 4 · Sabatini Brent · Nov 16, 2026
- Form 4 · Sawaf Aziz · Nov 16, 2026
- Schedule 13G · State Street Corp · Nov 10, 2026
- Form 4 · de Verneuil Vanina · Nov 4, 2026
- Form 4 · Topalian Suzanne Louise · Oct 28, 2026